A Phase 1/2 Study Evaluating Brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Seattle Genetics, Inc
Start Date
February 22, 2016
End Date
June 27, 2019
Administered By
Duke Cancer Institute
Awarded By
Seattle Genetics, Inc
Start Date
February 22, 2016
End Date
June 27, 2019